Thus, to further explore the therapeutic target of ADSCs for treating liver fibrosis, we investigated the expression of key mediators of TGF-β1/SMAD signaling including TGF-β1, SMAD3 and p-SMAD3. Here, TGFB1 is linked to Hepatic fibrosis.